170 related articles for article (PubMed ID: 36189254)
1. Exploration of the underlying biological differences and targets in ovarian cancer patients with diverse immunotherapy response.
Chen J; Chen S; Dai X; Ma L; Chen Y; Bian W; Sun Y
Front Immunol; 2022; 13():1007326. PubMed ID: 36189254
[TBL] [Abstract][Full Text] [Related]
2. Cancer-Associated Fibroblasts Affect Tumor Metabolism and Immune Microenvironment in Gastric Cancer and Identification of Its Characteristic Genes.
Gao C; Liu F; Ye Q; Guo A
J Oncol; 2023; 2023():1424589. PubMed ID: 36755806
[TBL] [Abstract][Full Text] [Related]
3. Research into the biological differences and targets in lung cancer patients with diverse immunotherapy responses.
Zhang X; Wu X; Huang H; Du K; Nie Y; Su P; Li Y
Front Immunol; 2022; 13():1014333. PubMed ID: 36189290
[TBL] [Abstract][Full Text] [Related]
4. PDP1 Promotes Cell Malignant Behavior and Is Associated with Worse Clinical Features in Ovarian Cancer Patients: Evidence from Bioinformatics and In Vitro Level.
Song Y; Zhang J; Zhang L; Zhang S; Shen C
Comput Math Methods Med; 2022; 2022():7397250. PubMed ID: 36276992
[TBL] [Abstract][Full Text] [Related]
5. Identifying potential targets for lung cancer intervention by analyzing the crosstalk of cancer-associated fibroblasts and immune and metabolism microenvironment.
Wei S; Bao M; Zhu Y; Zhang W; Jiang L
Environ Toxicol; 2023 Aug; 38(8):1951-1967. PubMed ID: 37186041
[TBL] [Abstract][Full Text] [Related]
6. Machine learning identifies characteristics molecules of cancer associated fibroblasts significantly correlated with the prognosis, immunotherapy response and immune microenvironment in lung adenocarcinoma.
Wang Q; Zhang X; Du K; Wu X; Zhou Y; Chen D; Zeng L
Front Oncol; 2022; 12():1059253. PubMed ID: 36439484
[TBL] [Abstract][Full Text] [Related]
7. Machine learning developed a CD8
Chen R; Zheng Y; Fei C; Ye J; Fei H
Sci Rep; 2024 Mar; 14(1):5794. PubMed ID: 38461331
[TBL] [Abstract][Full Text] [Related]
8. Pan-cancer analyses and molecular subtypes based on the cancer-associated fibroblast landscape and tumor microenvironment infiltration characterization reveal clinical outcome and immunotherapy response in epithelial ovarian cancer.
Zou R; Jiang Q; Jin T; Chen M; Yao L; Ding H
Front Immunol; 2022; 13():956224. PubMed ID: 36032075
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer.
Xu F; Liu T; Zhou Z; Zou C; Xu S
Front Immunol; 2021; 12():749369. PubMed ID: 34745121
[TBL] [Abstract][Full Text] [Related]
10. A novel tumor mutational burden-based risk model predicts prognosis and correlates with immune infiltration in ovarian cancer.
Wang H; Liu J; Yang J; Wang Z; Zhang Z; Peng J; Wang Y; Hong L
Front Immunol; 2022; 13():943389. PubMed ID: 36003381
[TBL] [Abstract][Full Text] [Related]
11. Identification and Validation of the Diagnostic Characteristic Genes of Ovarian Cancer by Bioinformatics and Machine Learning.
Liu J; Liu L; Antwi PA; Luo Y; Liang F
Front Genet; 2022; 13():858466. PubMed ID: 35719392
[No Abstract] [Full Text] [Related]
12. Comprehensive bioinformatic analysis constructs a CXCL model for predicting survival and immunotherapy effectiveness in ovarian cancer.
Li S; Zou D; Liu Z
Front Pharmacol; 2023; 14():1127557. PubMed ID: 36969851
[No Abstract] [Full Text] [Related]
13. Identification of peripheral blood immune infiltration signatures and construction of monocyte-associated signatures in ovarian cancer and Alzheimer's disease using single-cell sequencing.
Zhao S; Ye B; Chi H; Cheng C; Liu J
Heliyon; 2023 Jul; 9(7):e17454. PubMed ID: 37449151
[TBL] [Abstract][Full Text] [Related]
14. Construction of an Immune Cell Infiltration Score to Evaluate the Prognosis and Therapeutic Efficacy of Ovarian Cancer Patients.
Liu J; Wang Y; Yuan S; Wei J; Bai J
Front Immunol; 2021; 12():751594. PubMed ID: 34745124
[TBL] [Abstract][Full Text] [Related]
15. Identification of three molecular subtypes based on immune infiltration in ovarian cancer and its prognostic value.
Liu J; Tan Z; He J; Jin T; Han Y; Hu L; Song J; Huang S
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33043974
[TBL] [Abstract][Full Text] [Related]
16. P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling.
de Almeida Chuffa LG; de Moura Ferreira G; Lupi LA; da Silva Nunes I; Fávaro WJ
J Ovarian Res; 2018 Jan; 11(1):8. PubMed ID: 29343281
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy response and microenvironment provide biomarkers of immunotherapy options for patients with lung adenocarcinoma.
Zhan X; Feng S; Zhou X; Liao W; Zhao B; Yang Q; Tan Q; Shen J
Front Genet; 2022; 13():1047435. PubMed ID: 36386793
[No Abstract] [Full Text] [Related]
18. Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer.
Fu W; Feng Q; Tao R
Medicine (Baltimore); 2024 Apr; 103(16):e37783. PubMed ID: 38640321
[TBL] [Abstract][Full Text] [Related]
19. Construction and validation of immune-related LncRNAs classifier to predict prognosis and immunotherapy response in laryngeal squamous cell carcinoma.
Wang X; Pan Y; Ou Y; Duan T; Zou Y; Zhou X
World J Surg Oncol; 2022 May; 20(1):164. PubMed ID: 35606755
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of immune microenvironment in ovarian cancer and its clinical significance: a retrospective study.
Gao Y; Chen L; Cai G; Xiong X; Wu Y; Ma D; Li SC; Gao Q
Oncoimmunology; 2020; 9(1):1760067. PubMed ID: 32391193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
